@article{fdi:010076584,
  title = {{P}hylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery},
  author = {{T}ouret, {F}. and {B}aronti, {C}{\'e}cile and {G}oethals, {O}. and {V}an {L}oock, {M}. and {L}amballerie, {X}. de and {Q}uerat, {G}.},
  editor = {},
  language = {{ENG}},
  abstract = {{D}engue fever is the most widespread of the human arbovirus diseases, with approximately one third of the world's population at risk of infection. {D}engue viruses are members of the genus {F}lavivirus (family {F}laviviridae) and, antigenically, they separate as four closely related serotypes (1-4) that share 60-75% amino acid homology. {T}his genetic diversity complicates the process of antiviral drug discovery. {T}hus, currently no approved dengue specific therapeutic treatments are available. {W}ith the aim of providing.an efficient tool for dengue virus drug discovery, a collection of nineteen dengue viruses, representing the genotypic diversity within the four serotypes, was developed. {A}fter phylogenetic analysis of the full-length genomes, we selected relevant strains from the {EVA}g collection at {A}ix-{M}arseille {U}niversity and completed the virus collection, using a reverse genetic system based on the infectious sub-genomic amplicons technique. {F}inally, we evaluated this dengue virus collection against three published dengue inhibitory compounds. {NITD}008, which targets the highly conserved active site of the viral {NS}5 polymerase enzyme, exhibited similar antiviral potencies against each of the different dengue genotypes in the panel. {C}ompounds targeting less conserved protein subdomains, such as the capsid inhibitor {ST}-148, or {SDM}25{N}, a partial derivative opioid receptor antagonist which indirectly targets {NS}4{B}, exhibited larger differences in potency against the various genotypes of dengue viruses. {T}hese results illustrate the importance of a phylogenetically based dengue virus reference panel for dengue antiviral research. {T}he collection developed in this study, which includes such representative dengue viruses, has been made available to the scientific community through the {E}uropean {V}irus {A}rchive to evaluate novel {DENV} antiviral candidates.},
  keywords = {{D}engue virus ; {P}hylogenetic analysis ; {R}everse genetic ; {D}rug discovery ; {V}irus panel ; {D}engue inhibitors},
  booktitle = {},
  journal = {{A}ntiviral {R}esearch},
  volume = {168},
  numero = {},
  pages = {109--113},
  ISSN = {0166-3542},
  year = {2019},
  DOI = {10.1016/j.antiviral.2019.05.005},
  URL = {https://www.documentation.ird.fr/hor/fdi:010076584},
}